Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease
Wischik, C. M., Stefanacci, R., Bentham, P., Gauthier, S., Zetterberg, H., Wilcock, G. K., Froelich, L., Burns, A., MacSweeney, E., Ballard, C., Yu, J., Choon, T. S., Asvatourian, V., Muehlemann, N., Priel, J., Kook, K., Sullivan, T., Downie, D., Miller, S., Pringle, C., Storey, J. M. D., Baddeley, T., Harrington, C. R., Penny, L. K., Arastoo, M., Staff, R., Sandu, A., Shiells, H., Lo, S., Nazlee, N., Evans, E., Hull, C., Schelter, B. O.
The Journal of Prevention of Alzheimer's Disease, vol. 13, no. 3, 100480
Comparative study of the structural, optical and photocatalytic properties of strontium doped β-tricalcium phosphate (Ca3(PO4)2) toward degradation of Rhodamine B
Jadhav, C. H., Gibson, I. R., Pagare, P., Skakle, J. M.
Materials Chemistry and Physics: Sustainability and Energy, vol. 6, 100053